Azora Therapeutics, Inc.（AZR）财务数据AZRAzora Therapeutics, Inc.

Evaluating the bottom line, Azora Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 352.59%, provide a clear picture of how effectively AZR converts its operational activities into shareholder value.

In the context of the broader market, AZR competes directly with industry leaders such as CUPR and AEON. With a market capitalization of $9.86M, it holds a significant position in the sector. When comparing efficiency, AZR's gross margin of N/A stands against CUPR's -1.29% and AEON's N/A. Such benchmarking helps identify whether Azora Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The financial performance shows a concerning trend with fluctuating revenues and net income. For example, the total revenue for Q3 2026 was 11,504,434 USD, but it dropped to 2,951,623 USD in Q1 2027. The gross margin has remained low, around 6.22% to 6.88%, which is not favorable for long-term growth.